Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Depreciation & Amortization (CF): 2022-2024

Historic Depreciation & Amortization (CF) for Addex Therapeutics (ADXN) over the last 3 years, with Dec 2024 value amounting to -$269.8 billion.

  • Addex Therapeutics' Depreciation & Amortization (CF) fell 5.61% to -$269.8 billion in Q4 2024 from the same period last year, while for Dec 2024 it was -$269.8 billion, marking a year-over-year decrease of 209.09%. This contributed to the annual value of $295,679 for FY2024, which is 13.20% down from last year.
  • According to the latest figures from Q4 2024, Addex Therapeutics' Depreciation & Amortization (CF) is -$269.8 billion, which was down 779,064,988.99% from $34,626 recorded in Q3 2024.
  • In the past 5 years, Addex Therapeutics' Depreciation & Amortization (CF) registered a high of $168.1 billion during Q2 2023, and its lowest value of -$269.8 billion during Q4 2024.
  • Over the past 3 years, Addex Therapeutics' median Depreciation & Amortization (CF) value was $79,406 (recorded in 2023), while the average stood at -$29.8 billion.
  • Over the last 5 years, Addex Therapeutics' Depreciation & Amortization (CF) had its largest YoY gain of 194,303,155.50% in 2023, and its largest YoY loss of 325,276,587.58% in 2023.
  • Over the past 3 years, Addex Therapeutics' Depreciation & Amortization (CF) (Quarterly) stood at $78,524 in 2022, then tumbled by 325,276,587.58% to -$255.4 billion in 2023, then dropped by 5.61% to -$269.8 billion in 2024.
  • Its Depreciation & Amortization (CF) stands at -$269.8 billion for Q4 2024, versus $34,626 for Q3 2024 and $127,520 for Q2 2024.